Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$40.1B
79M shares
52-week range
$500.61 – $769.98
4% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
P/S (TTM)
9.1
EV / FCF (TTM)
33.7
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
www.idexx.comNo one on the platform currently holds IDXX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 48,504 | $27.3M |
| Bridgewater Associatesas of 2026-03-31 | 10,314 | $5.8M |
| Execution date | Ratio |
|---|---|
| 2015-06-16 | 2-for-1 |
| 2007-11-27 | 2-for-1 |
No one on the platform has traded IDXX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 43.5% | 41.9% | 39.8% | — | — | — |
| Rev. Growth % | 10.4% | 9.7% | ||||
| Profit Margin % | 24.6% | 22.8% | 19.6% | |||
| Free Cash Flow Margin % | 24.5% | 19.5% | 17.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +6.5% on the P/E track.
At today's price, your expected annual return is +11.6% on the P/E track.
At today's price, your expected annual return is +16.1% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $4.7B | +10.2% | $14.77 | $14.71–$14.82 | 34.6× | 10 |
| 2027 | $5.1B | +8.8% | $16.77 | $16.34–$17.09 | 30.5× | 10 |
| 2028 | $5.6B | +9.1% | $19.00 | $18.37–$19.79 | 26.9× | 9 |
| 2029 | $6.2B | +10.3% | $22.08 | $21.83–$22.36 | 23.2× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $3.94 | $4.27 | +8.4% |
| 2026-05-05 | $3.41 | $3.47 | +1.8% |
| 2026-02-02 | $2.93 | $3.08 | +5.1% |
| 2025-11-03 | $3.14 | $3.40 | +8.3% |
| 2025-08-04 | $3.28 | $3.63 | +10.7% |
| 2025-05-01 | $2.85 | $2.96 | +3.9% |
| 2025-02-03 | $2.39 | $2.62 | +9.6% |
| 2024-10-31 | $2.68 |
| $2.80 |
| +4.5% |
| $50.0B |
| — |
| CAHCardinal Health, Inc. | $233.63 | -0.40% | $54.7B | — |
| CORCencora, Inc. | $325.87 | +1.34% | $63.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
$IDXX Never good seeing a director selling his own stock at a 52w low
View on StockTwits ↗
$IDXX printed a new 52-week low today
View on StockTwits ↗$IDXX printed a new 52-week low today
View on StockTwits ↗
$ZOMDF unfortunately both $IDXX and $ZTS saying the vet market is getting worse and they both aren’t seeing signs of a recovery in August :((
View on StockTwits ↗
$IDXX Price: $556.93 (+2.03%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±1.49% RSI: 45.9 | Momentum: Moderate Volume: -26.8% vs avg Volatility: 1.90% Support: $538.20 | Resistance: $624.15 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
View on StockTwits ↗
$ZOMDF The bullish picture is getting much clearer: • Q2 revenue $9.5M, +37% YoY • Diagnostics +77%, driven by accelerating recurring consumables/utilization • Development Services already producing meaningful revenue and opening opportunities in animal + human health • Operating expenses down ~20%; adjusted EBITDA loss cut ~59% • $44.1M liquidity, essentially no funded debt, shares stayed ~980M through Q2 • PulseVet, Assisi, TRUFORMA, TRUVIEW & VETGuardian alone address >$2B U.S. TAM • Add international expansion, Development Services, HT7/hematology, new assays, Oxford/licensing and the broader pipeline, and the practical opportunity could be roughly $15B–$30B+ by our estimate • Management is actively focused on international growth, strategic partnerships and acquisitions The key: Zomedica doesn’t need huge market share. Even a few percent of the opportunities already available could support $75M–$100M+ revenue . $IDXX $SPY $BTC.X $SOXL
View on StockTwits ↗
$IDXX An update on my Idexx analysis. Read it here: https://seekingalpha.com/article/4933707-idexx-laboratories-worth-the-premium
View on StockTwits ↗
$ZOMDF https://stocks.apple.com/AuceynX_eSKqIpdrZWAuppg $IDXX $SPY $SOXL $BTC.X
View on StockTwits ↗$ZOMDF https://stocks.apple.com/AuceynX_eSKqIpdrZWAuppg $IDXX $SPY $SOXL $BTC.X
View on StockTwits ↗$ZOMDF strong organic and reported growth; * very strong Diagnostics performance; * recurring consumables momentum; * meaningful expense reductions; * sharply narrower losses; * improved cash efficiency. $IDXX $SPY $PLUG
View on StockTwits ↗
Wall St is expecting 3.72 EPS for $IDXX Q3 [Reporting 11/03 BMO] http://www.estimize.com/intro/idxx?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-4-idexx-laboratories-inc-stock/ $IDXX IDEXX Laboratories Earnings Transcript
View on StockTwits ↗
$IDXX Corrected information below: Idexx Laboratories reports Q2 EPS $4.27, consensus $3.93 Reports Q2 revenue $1.22B, consensus $1.2B. "Our Q2 results reflect the strength of our Technology for Life strategy, with continued innovation across our Catalyst, Fecal Dx, and IDEXX inVue Dx platforms supporting deeper customer adoption and higher diagnostic utilization," said CEO Mike Erickson. "This is the kind of durable, compounding growth we're building for the long term, helping veterinarians see more and do more for their patients while creating lasting value for our shareholders."
View on StockTwits ↗$IDXX Idexx Laboratories raises FY26 EPS view to $14.69-$14.94 from $14.45-$14.90 2026 EPS consensus $14.66. Narrows 2026 revenue view to $4.70B-$4.745B from $4.675B-$4.760B, consensus $4.71B.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.